logo
[breadcrumb_custom]

Day: January 7, 2021

VIPS stock
Trading Signals

Gilead Sciences (GILD) Has To Explore Ways to Grow Further

The healthcare firm Gilead Sciences Inc. (GILD) has lost nearly 5 percent of its stock over the past year. This arose even after the company’s drug was approved for COVID-19 therapy. Gilead Sciences specializes in the prevention of HIV as well as infectious diseases, including hepatitis C. The conventional portfolio of the company, however, can no longer support fast growth rates. Overall, in the third quarter of 2020, Gilead Sciences’ revenues rose 18 percent year on year to $6.49 billion, but much of the increase was provided by Veklury, the first FDA-approved medicine to treat COVID-19. After only gaining regulatory